Commentary|Podcasts|November 17, 2026

ESMO 2026 Data Highlight ADC Activity in Brain Metastases and TNBC

Fact checked by: Ashling Wahner

Drs Nunnery and Premji discussed breast cancer trials from ESMO 2026 that improved PFS without improving OS, as well as key ADC and brain metastasis data.

Breast Cancer Briefing, hosted by Sara Nunnery, MD, MSCI, a breast medical oncologist and the director of Breast Cancer Research at Tennessee Oncology in Nashville, is a podcast series that breaks down the latest news in breast cancer research, one conversation at a time.

In this episode, Dr Nunnery sat down with Sarah Premji, MD, a breast medical oncologist at Sarah Cannon Research Institute Oncology Partners and the assistant director of breast cancer research at Sarah Cannon Research Institute in Nashville, Tennessee.

The experts discussed trials that were presented at the 2026 ESMO Congress. In the phase 3 KEYNOTE-B49 trial (NCT04895358), adding pembrolizumab (Keytruda) to chemotherapy for PD-L1–positive, hormone receptor–positive, HER2-negative metastatic disease yielded a higher median PFS vs placebo plus chemotherapy, but no OS benefit. Dr Premji noted that the PFS benefit appeared concentrated in patients with a PD-L1 combined positive score above 10. She also said that the phase 3 FINER trial (NCT04650581) of fulvestrant (Faslodex) plus ipatasertib (GDC-0068/RG7440) showed a PFS benefit vs placebo plus fulvestrant, but that the investigational combination was associated with diarrhea in most patients, which she said limits the combination's potential role in this setting. The experts also discussed that in the final phase 3 NSABP B-42 trial (NCT00382070) analysis, extended letrozole (Femara) treatment improved disease-free survival and reduced distant recurrence at 16 years without improving OS.

Drs Nunnery and Premji then highlighted data in triple-negative disease and brain metastases. In the final OS analysis of the phase 3 OptiTROP-Breast01 trial (NCT05347134), sacituzumab tirumotecan (MK-2870/SKB264) produced a higher median than chemotherapy. In a subgroup analysis of the phase 3 TROPION-Breast02 trial (NCT05374512), datopotamab deruxtecan-dlnk (Datroway) improved central nervous system (CNS) PFS vs chemotherapy.

Dr Premji said she would “take [the phase 2 trial of tucatinib (Tukysa) after local therapy for isolated CNS progression] to clinic right away.” She described ctDNA monitoring as helpful but not yet practice changing.


Related to this article